MAIMON RESEARCH LLC: A NEW START RESEARCH AGENDA IN HEALTH TECHNOLOGY ASSESSMENT

SUPPORTING THE CREDIBILITY, EVALUATION AND REPLICATION OF VALUE CLAIMS FOR PHARMACEUTICAL PRODUCTS AND DEVICES

Maimon Research LLC is a long-established boutique consulting company specializing in health technology assessment, together with advising and implementing market access strategies to support pharmaceutical products and devices over their life cycle.

The focus of Maimon Research is on distance education in health technology assessment to provide a skill set for developing  claims for pharmaceutical products and devices that meet the standards of normal science: value claims that are credible, evaluable, and replicable.

A particular focus for Maimon Research is on measurement, in particular the role of the axioms of representational measurement to support disease specific latent trait claims . This is typically overlooked in HTA both for multiattribute claims that attempt falsely to value health state descriptions and disease specific claims that are only ordinal summed scores.

This sets Maimon Research apart from other health technology assessment consultants and academic groups who support the mainstream in health technology assessment focused on the invention of value claims that fail the standards of fundamental measurement. Unlike competitors, Maimon Research rejects the pseudoscience of assumption driven modeled value claims, offering instead a unique and methodologically acceptable approach to credible claims, their assessment, and replication in target patient populations.

Maimon Research puts to one side the approximate information reference case meme promoted by academic and other leaders in health technology assessment; a false belief system that has lasted for over 50 years. It has to be abandoned in favor of value assessment frameworks that make sense for formulary committees. Instead, Maimon Research offers a new start in technology assessment with value claims that support the standards of normal science and the axioms of representational measurement theory.

Maimon Research Services:

•developing value claims that are credible, evaluable, and replicable through supporting health technology assessments that meet standards of normal science

•supporting payers in developing standards for formulary evaluation that are meaningful and meet the standards of normal science

•developing formulary submission protocols for comparative claims validation

•ensuring claims reflect the needs of patients through outcomes instruments that are patient centric

•supporting the rejection of invalid claims, such as lifetime cost per QALY models, by formulary committees

•seminars and training programs to support the new start research agenda